Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer

NCT00435409 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00435409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
June 30, 2011
Enrollment
442 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms